PT1119567E - Derivados de quinazolina - Google Patents
Derivados de quinazolinaInfo
- Publication number
- PT1119567E PT1119567E PT99947758T PT99947758T PT1119567E PT 1119567 E PT1119567 E PT 1119567E PT 99947758 T PT99947758 T PT 99947758T PT 99947758 T PT99947758 T PT 99947758T PT 1119567 E PT1119567 E PT 1119567E
- Authority
- PT
- Portugal
- Prior art keywords
- sub
- sup
- alkyl
- optionally substituted
- compounds
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- -1 cyano, amino Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Seal Device For Vehicle (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98402496 | 1998-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1119567E true PT1119567E (pt) | 2005-08-31 |
Family
ID=8235527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99947758T PT1119567E (pt) | 1998-10-08 | 1999-10-05 | Derivados de quinazolina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7262201B1 (enExample) |
| EP (1) | EP1119567B1 (enExample) |
| JP (2) | JP2002527436A (enExample) |
| KR (1) | KR100860295B1 (enExample) |
| CN (1) | CN1161352C (enExample) |
| AT (1) | ATE294796T1 (enExample) |
| AU (1) | AU756556B2 (enExample) |
| BR (1) | BR9914326A (enExample) |
| CA (1) | CA2344290C (enExample) |
| DE (1) | DE69925141T2 (enExample) |
| DK (1) | DK1119567T3 (enExample) |
| ES (1) | ES2241324T3 (enExample) |
| HK (1) | HK1039126B (enExample) |
| IL (2) | IL142359A0 (enExample) |
| NO (1) | NO322644B1 (enExample) |
| NZ (1) | NZ510434A (enExample) |
| PT (1) | PT1119567E (enExample) |
| WO (1) | WO2000021955A1 (enExample) |
| ZA (1) | ZA200102655B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039206D1 (de) | 1999-11-05 | 2008-07-24 | Astrazeneca Ab | Neue Quinazolin-Derivate |
| WO2001066099A2 (en) * | 2000-03-06 | 2001-09-13 | Astrazeneca Ab | Use of quinazoline derivatives as angiogenesis inhibitors |
| BR0109828A (pt) | 2000-04-07 | 2002-12-17 | Astrazeneca Ab | Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| OA12291A (en) | 2000-06-22 | 2004-03-18 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatmentof abnormal cell growth. |
| CN1267431C (zh) * | 2000-06-28 | 2006-08-02 | 阿斯特拉曾尼卡有限公司 | 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途 |
| KR100821446B1 (ko) | 2000-08-21 | 2008-04-10 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| JP2004509115A (ja) * | 2000-09-15 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SI1318997T1 (sl) | 2000-09-15 | 2006-12-31 | Vertex Pharma | Pirazolne spojine, uporabne kot inhibitorji protein-kinaze |
| ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| JP4253188B2 (ja) | 2000-12-21 | 2009-04-08 | グラクソ グループ リミテッド | 血管新生制御剤としてのピリミジンアミン |
| PT1355905E (pt) * | 2000-12-21 | 2007-05-31 | Vertex Pharma | Compostos de pirazole úteis como inibidores de proteínaquinase |
| EP1381599B1 (en) | 2001-04-19 | 2008-09-24 | Astrazeneca AB | Quinazoline derivatives |
| RU2332415C2 (ru) * | 2001-04-27 | 2008-08-27 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, полезные в качестве ингибиторов протеинкиназы |
| US7132427B2 (en) | 2001-06-21 | 2006-11-07 | Ariad Pharmaceuticals, Inc. | Quinazolines and uses thereof |
| MXPA04006260A (es) * | 2001-12-24 | 2005-03-31 | Astrazeneca Ab | Derivados de quinazolina sustituidos como inhibidores de cinasas aurora. |
| ES2381781T3 (es) * | 2002-02-01 | 2012-05-31 | Astrazeneca Ab | Compuestos de quinazolina |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| KR20050032105A (ko) | 2002-08-02 | 2005-04-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물 |
| DK1562955T3 (da) | 2002-11-04 | 2008-06-02 | Astrazeneca Ab | Quinazolinderivater som Src-tyrosinkinaseinhibitorer |
| AU2003290313B2 (en) | 2002-12-24 | 2007-05-10 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| BRPI0414489A8 (pt) | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| CA2542076C (en) * | 2003-10-14 | 2013-02-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
| US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| CN101072758B (zh) * | 2004-10-12 | 2013-07-31 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| AU2005306458B2 (en) | 2004-11-17 | 2011-02-17 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| NZ567241A (en) | 2005-09-30 | 2010-08-27 | Miikana Therapeutics Inc | Substituted pyrazole compounds |
| NZ594385A (en) | 2005-11-03 | 2013-02-22 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| EP1994024A2 (en) * | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives |
| EP2152694A2 (en) | 2007-05-02 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| NZ582879A (en) | 2007-07-31 | 2012-03-30 | Vertex Pharma | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| NZ587907A (en) | 2008-03-17 | 2012-09-28 | Ambit Biosciences Corp | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| WO2010027921A1 (en) | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
| PT2387563E (pt) | 2009-01-16 | 2013-03-25 | Exelixis Inc | Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2013050437A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| PL3046584T3 (pl) | 2013-09-16 | 2017-11-30 | Astrazeneca Ab | Terapeutyczne polimeryczne nanocząstki i sposoby ich wytwarzania i stosowania |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9771333B2 (en) | 2013-11-20 | 2017-09-26 | Signalchem Lifesciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| WO2017062500A2 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10799503B2 (en) | 2016-12-01 | 2020-10-13 | Ignyta, Inc. | Methods for the treatment of cancer |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| CN113549053B (zh) * | 2020-04-23 | 2022-09-13 | 沈阳中化农药化工研发有限公司 | 一种吡唑喹（唑）啉醚类化合物及其应用 |
| EP4201936A4 (en) * | 2020-08-20 | 2024-02-21 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | HETEROAROMATIC RING COMPOUND AS A RET KINASE INHIBITOR AND PRODUCTION AND USE THEREOF |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870725A (en) | 1971-03-30 | 1975-03-11 | Lilly Industries Ltd | Nitrothiazole derivatives |
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| WO1992016527A1 (fr) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | Derive de pyridine substitue en position 2, sa production, et bactericide d'agrohorticulture |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US6001970A (en) | 1994-11-07 | 1999-12-14 | Merck & Co., Inc | Modified human neuropeptide Y1 Receptors |
| IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
| TW334434B (en) | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| PT912559E (pt) * | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
| KR100622323B1 (ko) | 1996-10-01 | 2006-11-30 | 교와 핫꼬 고교 가부시끼가이샤 | 질소-함유헤테로고리화합물 |
| US6316479B1 (en) * | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
-
1999
- 1999-10-05 CA CA002344290A patent/CA2344290C/en not_active Expired - Fee Related
- 1999-10-05 NZ NZ510434A patent/NZ510434A/en not_active IP Right Cessation
- 1999-10-05 ES ES99947758T patent/ES2241324T3/es not_active Expired - Lifetime
- 1999-10-05 IL IL14235999A patent/IL142359A0/xx unknown
- 1999-10-05 BR BR9914326-7A patent/BR9914326A/pt not_active Application Discontinuation
- 1999-10-05 EP EP99947758A patent/EP1119567B1/en not_active Expired - Lifetime
- 1999-10-05 DK DK99947758T patent/DK1119567T3/da active
- 1999-10-05 DE DE69925141T patent/DE69925141T2/de not_active Expired - Lifetime
- 1999-10-05 AT AT99947758T patent/ATE294796T1/de active
- 1999-10-05 WO PCT/GB1999/003295 patent/WO2000021955A1/en not_active Ceased
- 1999-10-05 KR KR1020017004370A patent/KR100860295B1/ko not_active Expired - Fee Related
- 1999-10-05 AU AU61128/99A patent/AU756556B2/en not_active Ceased
- 1999-10-05 HK HK02100744.7A patent/HK1039126B/en not_active IP Right Cessation
- 1999-10-05 PT PT99947758T patent/PT1119567E/pt unknown
- 1999-10-05 JP JP2000575861A patent/JP2002527436A/ja not_active Withdrawn
- 1999-10-05 CN CNB998118613A patent/CN1161352C/zh not_active Expired - Fee Related
- 1999-10-05 US US09/806,836 patent/US7262201B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 ZA ZA200102655A patent/ZA200102655B/en unknown
- 2001-04-01 IL IL142359A patent/IL142359A/en not_active IP Right Cessation
- 2001-04-06 NO NO20011739A patent/NO322644B1/no not_active IP Right Cessation
-
2011
- 2011-01-14 JP JP2011006012A patent/JP2011126888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU756556B2 (en) | 2003-01-16 |
| EP1119567B1 (en) | 2005-05-04 |
| DE69925141D1 (de) | 2005-06-09 |
| CA2344290C (en) | 2009-06-02 |
| IL142359A (en) | 2008-11-03 |
| NZ510434A (en) | 2003-10-31 |
| NO322644B1 (no) | 2006-11-13 |
| CN1161352C (zh) | 2004-08-11 |
| CA2344290A1 (en) | 2000-04-20 |
| DE69925141T2 (de) | 2006-04-27 |
| KR100860295B1 (ko) | 2008-09-25 |
| AU6112899A (en) | 2000-05-01 |
| WO2000021955A1 (en) | 2000-04-20 |
| CN1322202A (zh) | 2001-11-14 |
| HK1039126B (en) | 2005-09-30 |
| JP2002527436A (ja) | 2002-08-27 |
| ES2241324T3 (es) | 2005-10-16 |
| JP2011126888A (ja) | 2011-06-30 |
| US7262201B1 (en) | 2007-08-28 |
| EP1119567A1 (en) | 2001-08-01 |
| DK1119567T3 (da) | 2005-07-25 |
| NO20011739D0 (no) | 2001-04-06 |
| BR9914326A (pt) | 2001-06-26 |
| IL142359A0 (en) | 2002-03-10 |
| ATE294796T1 (de) | 2005-05-15 |
| ZA200102655B (en) | 2002-09-30 |
| HK1039126A1 (en) | 2002-04-12 |
| KR20010085890A (ko) | 2001-09-07 |
| NO20011739L (no) | 2001-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1119567E (pt) | Derivados de quinazolina | |
| DK0873319T3 (da) | Quinazolinderivater | |
| NO991423D0 (no) | Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF | |
| BR9707495A (pt) | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente | |
| BRPI0015203B8 (pt) | derivado de quinazolina, composição farmacêutica, e, uso de um composto | |
| BRPI0008128B8 (pt) | derivados de quinazolina, composições farmacêuticas contendo os mesmos, e, uso dos mesmos como inibidores de angiogênese | |
| BR0115454A (pt) | Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável |